Literature DB >> 137262

The effect of locally injected vasoactive amines on the elicitation of delayed-type hypersensitivity.

A Schwartz, P W Askenase, R K Gershon.   

Abstract

In previous work monoamine depletion due to treatment with reserpine was shown to decrease the elicitabiltiy of DTH responses in mice. In addition, treatment with monoamine oxidase inhibitors prevented the reserpine-induced decrease. These findings led to the suggestion that serotonin-induced increased vascular permeability is necessary to the development of DTH reactions, perhaps by allowing bone marrow-derived macrophage precursor cells, which are obligate components of DTH responses, to migrate through specialized venules into the site of the reaction. We have compared classical drug tachyphlaxis (temporary inhibition of the effects of a drug by prior treatment with agonists) to serotonin in vessels of mouse feet with local inhibition of DTH after serotonin pretreatment of mice. During the tachyphylactic period, DTH responses are depressed. This suggests that serotonin-induced tachyphylaxis of local endothelial receptors can be responsible for DTH inhibition. In contrast, local injection of histamine has no effect on DTH and this drug is a much less potent inducer of tachyphylaxis to serotonin-mediated vasoactive reactions. On the other hand, histamine can inhibit in vitro T cell reactions, which are not affected by serotonin. These data help to further the concept that serotonin plays an important role in the regulation of DTH in mice and that it probably does so by acting on vascular endothelium.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 137262

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Localization of leucocytes in sites of delayed-type hypersensitivity and in lymph nodes: dependence on vasoactive amines.

Authors:  P W Askenase; C M Metzler; R K Gershon
Journal:  Immunology       Date:  1982-10       Impact factor: 7.397

2.  Inflammatory response linked to oxazolone-indued cutaneous basophil hypersensitivity: effect of different immunomodulator and anti-inflammatory drugs.

Authors:  J Bure; F Degrand
Journal:  Agents Actions       Date:  1979-12

3.  Skin reactivity of unsensitized monkeys upon challenge with staphylococcal enterotoxin B: a new approach for investigating the site of toxin action.

Authors:  P H Scheuber; J R Golecki; B Kickhöfen; D Scheel; G Beck; D K Hammer
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

Review 4.  The role of lymphokines in delayed-type hypersensitivity reactions.

Authors:  C L Geczy
Journal:  Springer Semin Immunopathol       Date:  1984

5.  Cutaneous basophil anaphylaxis. Immediate vasopermeability increases and anaphylactic degranulation of basophils at delayed hypersensitivity reactions challenged with additional antigen.

Authors:  P W Askenase; R Debernardo; D Tauben; M Kashgarian
Journal:  Immunology       Date:  1978-11       Impact factor: 7.397

6.  Histamine 2 receptor-mediated immunomodulation in the mouse. I. Immunomodulation by the H2 agonist tolazoline.

Authors:  H Van Dijk; M Rapis; H E Jacobse-Geels; J M Willers
Journal:  Clin Exp Immunol       Date:  1979-03       Impact factor: 4.330

7.  Pharmacological studies on lymphocytes: 2. Effects of indole derivatives and their antagonists on the lymphocyte migration.

Authors:  I Paegelow; P Lange
Journal:  Agents Actions       Date:  1984-10

8.  Influence of reserpine on in vivo localization of injected lymph node cells in the mouse.

Authors:  A Bellavia; H S Micklem
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

9.  5-Hydroxytryptamine releasing activity in culture supernatants of guinea pig lymphocytes.

Authors:  M Hagen; I Paegelow; U Karnstedt
Journal:  Agents Actions       Date:  1984-10

10.  Use of 51Cr-labeled mononuclear cells for measuring the cellular immune response in mouse lungs.

Authors:  A Zarkower; W J Scheuchenzuber; F G Ferguson
Journal:  Infect Immun       Date:  1981-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.